New therapeutic standards with SHR-A 1811

This year’s ESMO Congress 2025 once again offered a wide range of new data on the treatment of HER2-positive breast cancer, including the interim analysis of the phase 3 HORIZON-Breast01 study presented by Erwei Song (Sun Yat-sen University, Guangzhou). The study compares SHR-A 1811 with pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer. It provides the first randomized data on this new HER2-targeted antibody-drug conjugate.